IC
FOLD

Innealta Capital’s Amicus Therapeutics FOLD Stock Holding History

Innealta Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-47
Closed -$466 – 726
2024
Q2 		$466 Buy
+47
New +$482 ﹤0.01% 1483

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Innealta Capital's FOLD Position: Q3 2024 in Review

Innealta Capital sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 47 shares — an estimated $466 sold.

Innealta Capital first reported a position in FOLD in Q2 2024 and held it in 1 quarter. The position peaked at $466 in Q2 2024. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Innealta Capital reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 47 Amicus Therapeutics shares in Q3 2024, an estimated $466.
  • Innealta Capital first reported a position in Amicus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Amicus Therapeutics position peaked at $466 in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.